 |
|
|
| |
Risk of multiple drug-drug interactions (DDIs) in
HCV patients receiving pangenotypic DAAs (pDAAs):
A complex drug interaction scenario first time
evaluated in German patients
|
| |
| |
EASL International Liver Congress, June 23-26, 2021
F. Tacke1, G. Niess2, M. Gündogdu2, A. Hintz3, T. Umland3
1Charite - Universitatsmedizin Berlin, Department of Hepatology and Gastroenterology, Berlin, Germany, 2Gilead Sciences GmbH, Martinsried / Munich, Germany; 3Alexander Apotheke, Hamburg, Germany
|
| |
|
|
|
|
|
